Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.
Newser on MSN
Pfizer's New Flu Shot Could Be a 'Game Changer'
A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...
Lots more details about the fallout from STAT’s John Wilkerson. Read more here.
Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...
A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...
NDTV Profit on MSN
Biocon Eyes Acceleration Phase As USFDA Draft Guidelines Open Door To Cheaper Biosimilars: Kiran Mazumdar-Shaw
Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback